FIG
ALXN

Fortress Investment Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Fortress Investment Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,500
Closed -$228K – 195
2014
Q1 		$228K Buy
+1,500
New +$239K ﹤0.01% 121

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fortress Investment Group's ALXN Position: Q2 2014 in Review

Fortress Investment Group sold out of Alexion Pharmaceuticals (ALXN) in Q2 2014, closing a stake of 1,500 shares — an estimated $228K sold.

Fortress Investment Group first reported a position in ALXN in Q1 2014 and held it in 1 quarter. The position peaked at $228K in Q1 2014. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

  • Fortress Investment Group reported no remaining Alexion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Fortress Investment Group sold 1,500 Alexion Pharmaceuticals shares in Q2 2014, an estimated $228K.
  • Fortress Investment Group first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Fortress Investment Group's Alexion Pharmaceuticals position peaked at $228K in Q1 2014.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on Fortress Investment Group's 13F filing for Q2 2014, filed 14 Aug 2014.